Combined interferon and ribavirin therapy for chronic hepatitis C in Taiwan

Intervirology

Volumn 49, Issue 1-2, 2006, Pages 91-95

  Lai, Ming Yang ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Chronic hepatitis; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Interferon; Ribavirin

Indexed keywords

ALPHA INTERFERON; HEPATITIS B ANTIGEN; PEGINTERFERON ALPHA2B; RIBAVIRIN;

AGE DISTRIBUTION; BLOOD DONOR; CANCER INCIDENCE; CANCER RISK; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE TRANSMISSION; DRUG EFFECT; DRUG EFFICACY; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MONOTHERAPY; PREVALENCE; PRIORITY JOURNAL; SEROPREVALENCE; TAIWAN;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; RIBAVIRIN; SEROEPIDEMIOLOGIC STUDIES; TAIWAN;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 24944506409     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087269     Document Type: Conference Paper

References (42)

1. Di Bisceglie AM: Hepatitis C and hepatocellular carcinoma. Hepatology 1997;26:S34-S38.
2. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell RH, Akahane Y, Nishioka K, Purcell RH, Alter HJ: Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-675.
3. Seeff LB: Natural history of chronic hepatitis C. Hepatology 2002;36:S35-S46.
4. Lindsay KL: Therapy of hepatitis C: Overview. Hepatology 1997;26:S71-S77.
5. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M: Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999;131:174-181.
6. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
7. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492.
8. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-965.
9. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
10. Chen DS: From hepatitis to hepatoma: Lessons from type B viral hepatitis. Science 1993;262:369-370.
11. Chen DS, Kuo GC, Sung JL, Lai MY, Sheu JC, Chen PJ, Yang PM, Hsu HM, Chang MH, Chen CJ, et al: Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: The Taiwan experience. J Infect Dis 1990;162:817-822.
12. Moriya T, Koyama T, Tanaka J, Mishiro S, Yoshizawa H: Epidemiology of hepatitis C virus in Japan. Intervirology 1999;42:153-158.
13. Wu JS, Lu CF, Liu WT, Lin SY: Prevalence of antibodies to hepatitis C virus (anti-HCV) in different populations in Taiwan. Chinese J Microbiol Immunol 1991;24:55-60.
14. Sheu JC, Wang JT, Wang TH, Wang CY, Yang PM, Huang GT, Shih LN, Lee HS, Chen DS: Prevalence of hepatitis C viral infection in a community in Taiwan. Detection by synthetic peptide-based assay and polymerase chain reaction. J Hepatol 1993;17:192-198.
15. Lu SN, Chue PY, Chen HC, Wu MH, Chen IL, Huang JF, Wang JH, Peng CF, Shih CH, You SL, Lu CF, Chen CJ, Chang WY: Different viral aetiology of hepatocellular carcinoma between two hepatitis B and C endemic townships in Taiwan. J Gastroenterol Hepatol 1997;12:547-550.
16. Ho MS, Hsu CP, Yuh Y, King CC, Tsai JF, Mau YC, Hsu LC, Chao WH: High rate of hepatitis C infection in an isolated community: Persistent hyperendemicity or period-related phenomena. J Med Virol 1997;52:370-376.
17. Hwu NY, Fan CK, Chung WC, Wang CY, Hsueh YM, Chen HH, Lin CF, Su TT, Jang YS: Seroepidemiological study of hepatitis C virus infection in the Hsin-Chu Area, Taiwan. Tsu Chi Med J 1998;10:305-310.
18. Sun CA, Chen HC, Lu CF, You SL, Mau YC, Ho MS, Lin SH, Chen CJ: Transmission of hepatitis C virus in Taiwan: Prevalence and risk factors based on a nationwide survey. J Med Virol 1999;59:290-296.
19. Sun CA, Chen HC, Lu SN, Chen CJ, Lu CF, You SL, Lin SH: Persistent hyperendemicity of hepatitis C virus infection in Taiwan: The important role of iatrogenic risk factors. J Med Virol 2001;65:30-34.
20. Kao JH, Chen PJ, Lai MY, Yang PM, Sheu JC, Wang TH, Chen DS: Genotypes of hepatitis C virus in Taiwan and the progression of liver disease. J Clin Gastroenterol 1995;21:233-237.
21. 2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 2005;12:283-291.
22. Okuda K, Fujimoto I, Hanai A, Urano Y: Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987;47:4967-4972.
23. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
24. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC: Increase in primary liver cancer in the UK, 1979-94. Lancet 1997;350:1142-1143.
25. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA: The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Ann Intern Med 2003;139:817-823.
26. Sung JL, Chen DS: Hepatitis B surface antigen and antibody in liver disease in Taiwan. Proc 5th Asian-Pacific Congr Gastroenterol, Singapore, 1976, pp 265-269.
27. Chemello L, Cavalletto L, Bernardine E, Guido M, Pontisso P, Alverti A: The effect of interferon alfa and ribavirin combination therapy in naïve patients with chronic hepatitis C. J Hepatol 1995;23:S8-S12.
28. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, Chu JS, Chen DS: Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-1312.
29. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O: Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-87.
30. Fang SH, Lai MY, Hwang LH, Yang PM, Chen PJ, Chiang BL, Chen DS: Ribavirin enhances interferon-gamma levels in patients with chronic hepatitis C treated with interferon-alpha. J Biomed Sci 2001;8:484-491.
31. Liaw YF: Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995;22:1101-1108.
32. Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS: Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003;37:568-576.
33. Liu CJ, Chen PJ, Chen DS: A forgotten population with chronic hepatitis C infection: Subjects coinfected with hepatitis B virus. Hepatology 2004;40:266.
34. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, Novelli V, Cipolla A, Fabbri C, Pezzoli A, Roda E: Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141-147.
35. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Nishikawa M, Seki K, Matsuzawa Y: Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998;129:94-99.
36. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A: Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998;83:901-909.
37. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, Nawrocki M, Kruska L, Hensel F, Petry W, Haussinger D: Prognosis of chronic hepatitis C: Results of a large, prospective cohort study. Hepatology 1998;28:1687-1695.
38. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, Almasio P, Solinas A, Brouwer JT, Thomas H, Realdi G, Corrocher R, Schalm SW: Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997;27:201-205.
39. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H, Kawanishi M: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124-1130.
40. Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G: Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. Cancer 2000;89:53-59.
41. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T, Yao R, Albrecht J: The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 2000; 119: 1317-1323.
42. Cheng PN, Marcellin P, Bacon B, Farrell G, Parsons I, Wee T, Chang TT: Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: A better response in Chinese patients. J Viral Hepat 2004;11:418-426.